National Serology Reference Laboratory, St Vincent's Institute, Melbourne, Victoria, Australia.
PLoS One. 2010 Sep 9;5(9):e12631. doi: 10.1371/journal.pone.0012631.
Several clinical studies have shown that, relative to disease progression, HIV-1 isolates that are less fit are also less pathogenic. The aim of the present study was to investigate the relationship between viral fitness and control of viral load (VL) in acute and early HIV-1 infection. Samples were obtained from subjects participating in two clinical studies. In the PULSE study, antiretroviral therapy (ART) was initiated before, or no later than six months following seroconversion. Subjects then underwent multiple structured treatment interruptions (STIs). The PHAEDRA study enrolled and monitored a cohort of individuals with documented evidence of primary infection. The subset chosen were individuals identified no later than 12 months following seroconversion to HIV-1, who were not receiving ART. The relative fitness of primary isolates obtained from study participants was investigated ex vivo. Viral DNA production was quantified using a novel real time PCR assay. Following intermittent ART, the fitness of isolates obtained from 5 of 6 PULSE subjects decreased over time. In contrast, in the absence of ART the fitness of paired isolates obtained from 7 of 9 PHAEDRA subjects increased over time. However, viral fitness did not correlate with plasma VL. Most unexpected was the high relative fitness of isolates obtained at Baseline from PULSE subjects, before initiating ART. It is widely thought that the fitness of strains present during the acute phase is low relative to strains present during chronic HIV-1 infection, due to the bottleneck imposed upon transmission. The results of this study provide evidence that the relative fitness of strains present during acute HIV-1 infection may be higher than previously thought. Furthermore, that viral fitness may represent an important clinical parameter to be considered when deciding whether to initiate ART during early HIV-1 infection.
几项临床研究表明,与疾病进展相比,适应性较低的 HIV-1 分离株的致病性也较低。本研究旨在探讨病毒适应性与急性和早期 HIV-1 感染中病毒载量(VL)控制之间的关系。从参加两项临床研究的受试者中采集样本。在 PULSE 研究中,在血清转换前或不晚于六个月开始抗逆转录病毒治疗(ART)。然后,受试者接受多次结构治疗中断(STIs)。PHAEDRA 研究招募并监测了一组有明确原发性感染证据的队列。选择的亚组是在血清转换后不晚于 12 个月确定的、未接受 ART 的个体。研究参与者获得的原发性分离物的相对适应性在体外进行了研究。使用新型实时 PCR 测定法定量测定病毒 DNA 产生。间歇性 ART 后,6 名 PULSE 受试者中 5 名的分离物适应性随时间逐渐降低。相比之下,在没有 ART 的情况下,7 名 PHAEDRA 受试者的配对分离物适应性随时间逐渐增加。然而,病毒适应性与血浆 VL 无关。最出人意料的是,在开始 ART 之前,PULSE 受试者从基线获得的分离物具有较高的相对适应性。人们普遍认为,由于在传播过程中产生瓶颈,急性阶段存在的菌株适应性相对较低,而慢性 HIV-1 感染阶段存在的菌株适应性较高。这项研究的结果提供了证据,表明急性 HIV-1 感染期间存在的菌株的相对适应性可能高于先前的预期。此外,病毒适应性可能是决定在早期 HIV-1 感染期间是否开始 ART 时要考虑的重要临床参数。